Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Polivy + BR granted accelerated approval

August 2019—Genentech announced that the FDA has granted accelerated approval to Polivy (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan (rituximab) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who have received at least two prior therapies. Accelerated approval was granted based on complete response rates observed in the phase one-b/two GO29365 study, a randomized, controlled clinical trial.

Quanta Flash RF IgM, IgA assays cleared

August 2019—Inova Diagnostics announced FDA 510(k) clearance of its Quanta Flash RF IgM and Quanta Flash RF IgA assays. The chemiluminescent immunoassays are used in human sera and are indicated for the quantitative determination of IgM rheumatoid factor antibodies (Quanta Flash RF IgM) and the semiquantitative determination of IgA rheumatoid factor antibodies (Quanta Flash RF IgA). The presence

ResistancePlus GC gets breakthrough designation

August 2019—SpeeDx Pty. announced that the FDA has granted breakthrough device designation for its ResistancePlus GC, a molecular test providing ciprofloxacin susceptibility and resistance information to effectively treat N. gonorrhoeae. It is CE marked and cleared by the Therapeutic Goods Association for use in Europe, Australia, and New Zealand.

Binding Site TBE antigens, purified human CRP

August 2019—Binding Site’s Immunologicals Group added two native tick-borne encephalitis viral antigens to its line of products for in vitro diagnostic manufacturing and research applications. The standard version of the antigen as well as the premium version are for use as components in enzyme immunoassay testing procedures.

Qiagen, Inovio to develop CDx

August 2019—Qiagen and Inovio Pharmaceuticals will collaborate to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus. The partnership focuses on Inovio’s VGX-3100

OGT releases SureSeq NGS library prep kit

August 2019—Oxford Gene Technology has expanded its SureSeq portfolio with the SureSeq NGS Library Preparation Kit, a library preparation solution for hybridization-based target capture in next-generation sequencing. The kit includes a ready-to-use hybridization and wash buffer. OGT has also developed a library preparation automation workflow available for the Agilent Bravo NGS (Option A) instrument that aims to further reduce manual handling and save time.

FDA clears Bühlmann 
fCAL turbo

August 2019—Bühlmann Laboratories received FDA 510(k) clearance for its Bühlmann fCAL turbo in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool.

BD COR now CE-IVD marked

August 2019—BD announced the EU launch of its CE-IVD-marked BD COR, an automated, high-throughput molecular diagnostics system developed for large-capacity laboratories.

MARKETPLACE

TRENDING